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Final analysis of a phase II trial of concomitant docetaxel/radiation 
followed by consolidation docetaxel/cisplatin in unresectable stage 
IIIa and IIIb non small cell lung cancer- TAX-AU-6022 study
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Martin Olver, Ian N. 
Royal Adelaide Hospital, Adelaide, SA, Australia
Introduction: Non Small Cell Lung cancer (NSCLC) is a leading 
cause of cancer mortality in men and increasingly in women. In South 
Australia in 2000, 25% of cancer deaths were due to lung cancer in 
males and 14% in females. 8268 new cases were diagnosed in 2001. 
Approximately 25-40% patients present with Stage III disease. The 
current standard of care for these patients is platinum based concurrent 
chemo-radiation. There is a controversy regarding choice of chemo-
therapeutic agent, schedule and role of additional chemotherapy.
The present phase II study was designed to test taxanes as a radiosensi-
tiser. The primary end points were response rate, progression free and 
overall survival. The other goal of the study was to assess safety and 
efﬁcacy of consolidation chemotherapy.
Methods and Materials: Patients with a histological diagnosis of 
NSCLC, adequately staged as stage III by CT, FDG-PET scan and /or 
mediastinoscopy with good performance status were treated with week-
ly docetaxel at a dose of 30 mg/m2 for the duration of radical radio-
therapy. Four weeks later, patients were given four cycles of docetaxel 
and cisplatin at the dose of 75 mg/m2 q 3 weeks. Patients who remained 
in remission were offered prophylactic cranial radiation. The initial 12 
patients received Celecoxib 400 mg for 6 months. 
Results: The study started in March 2003. The study has enrolled 
twenty four patients to date. The majority had Stage IIIB tumors 
(13/24). 23 patients are evaluable for efﬁcacy and response. 21/23 
completed chemoradiation and 16/23 completed full treatment giving 
a compliance rate of 70%. 6 patients have received PCI so far. Best 
response was partial seen in 13/23 (57%). 3/23 had progressive disease. 
2 patients had non-evaluable disease due to early death. One of these 
patients had treatment-related mortality (gut perforation related to 
celecoxib use). 13/23 patients have died. 10 are alive and all of them, 
except one, are disease free giving an overall survival after 48 months 
follow-up of 43%. Loco-regional progression remains the most com-
mon site of treatment failure with 7 patients progressing loco-region-
ally and 4 distally. 
A total of 50 grade III and IV adverse events were recorded. 14/ 23 
(60%) had at least one grade III/IV adverse event. The most common 
grade III/IV side effects were pneumonitis in 8/23 (35%), esophagi-
tis (3/23), myelosuppression (3/23) and febrile neutropenia (5/23). 
Celecoxib seemed to aggravate toxicities. The initial 12 patients who 
received celecoxib had a total of 36 Gr III/IV toxicities while the last 
11 patients who did not receive celecoxib had a total of 14 Gr III/IV 
toxicities. 
Conclusion: Docetaxel is very active as a radiosensitiser with a 
response rate of 57% and an overall survival rate of 48%. The most 
important side effect was pneumonitis. Celecoxib use was associated 
with increased toxicity. The updated analysis on all 24 patients will be 
presented at the meeting including the effects of PCI on natural history, 
and the effects of celecoxib on efﬁcacy and sites of failure. 
We acknowledge Sanoﬁ-Aventis for supply of drug and study support, 
the Adelaide Clinical Trials and Educational Collaborative, and Nancy 
Olszewski for data collection. 
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The 7-years results of the surgical treatment of non-small cell lung 
cancer patients and the influence of neoadjuvant treatment
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Background: In this study from the years 2000 - 2006 we analyzed 
the group of 714 patients with non-small lung cancer (NSCLC) from 
university hospital and the inﬂuence of neoadjuvant treatment before 
surgary.
Methods: A total amount of 714 patients with primary NSCLC diag-
nosed and treated between 2000-2005 were analyzed. Of these patients 
566 (79%) were males and 148 (21%) were females. Age ranged from 
28 years to 84 years, with an average of 62.3 years. Of these patients 
4 (0.6%) were stage IA, 44 (6.1%) stage IB, 5 (0.7%) stage IIA, 
36 (5.0%) stage IIB, 9 (1.2%) stage III, 94 (13.1%) stage IIIA, 197 
(27.6%) stage IIIB and 260 (36.4%) stage IV (Mountain, C.F. 1997). In 
65 (9.1%) stage was unknown. The analyzed group represents the open 
group in which some enrolled patients are still alive.
Results: Of 714 patients 131 (18.3%) underwent radical resection, 94 
(72%) of all 131 radically resected underwent surgical treatment di-
rectly after the diagnosis and 37 (28%) underwent neoadjuvant therapy 
before surgery. In the group of 94 resected patients after diagnosis 
were stage IA 14 (10.7%) patients, IB 33 (25.2%), IIA 3 (2.3%), IIB 16 
(12.2%), IIIA 50 (38.2%), IIIB 12 (9.2%) and III 3 (2.3%) In this group 
74 (56.4%) patients underwent lobectomy, 25 (19.2%) atypical resec-
tion, 17 (12.8%) pneumonectomy and 15 (11.6%) bilobectomy. In the 
group of 37 patients with neoadjuvant treatment were 2 (5.4%) stage 
IIB, 26 (70.3%) IIIA, 6 (16.2%) stage IIIB, and III 2 (5.4%) patients. 
In this group of patients the most frequent was pneumonectomy, in 
24 (71%) patients, atypical resection underwent 3 (8%), lobectomy 7 
(20%) and bilobectomy in 3 (8%) patients. In the group of 37 patients 
with neoadjuvant therapy after diagnosis was median survival 34,1 
month and in the group of 94 patients with resection after diagnosis 
the median survival was not reached. The difference between this two 
groups is statistically signiﬁcant (p=0.006). The median survival in the 
group of all radically resected patients (No 131) was 44,8 month.
Conclusions: We concluded, that the neoadjuvant therapy did not 
inﬂuence the median survival of all group of surgically treated patients, 
although signiﬁcantly increases the ratio of radically resected patients. 
The difference between the group of patients operated after diagnoses 
and the group with neoadjuvant therapy was statistically signiﬁcant 
(p=0.006).
